BR9809173A - Adenovìrus alternativamente direcionados - Google Patents

Adenovìrus alternativamente direcionados

Info

Publication number
BR9809173A
BR9809173A BR9809173-5A BR9809173A BR9809173A BR 9809173 A BR9809173 A BR 9809173A BR 9809173 A BR9809173 A BR 9809173A BR 9809173 A BR9809173 A BR 9809173A
Authority
BR
Brazil
Prior art keywords
adenovirus
substrate
present
provides
trimer
Prior art date
Application number
BR9809173-5A
Other languages
English (en)
Inventor
Thomas J Wickham
Imre Kovesdi
Petrus W Roelvink
David Einfeld
Douglas E Brough
Alena Lizonova
Grant Yonehiro
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of BR9809173A publication Critical patent/BR9809173A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<B>ADENOVìRUS ALTERNATIVAMENTE DIRECIONADOS<D> A presente invenção provê um trímero compreendendo três monómeros, cada um tendo um terminal amino de uma proteína de fibra adenoviral e um domínio de trimerização. O trímero apresenta uma afinidade reduzida para um substrato nativo, em comparação com um trímero de fibra adenoviral nativo. A presente invenção provê, ainda, um adenovírus incorporando o trímero da presente invenção. A presente invenção também provê uma linhagem de célula expressando um receptor de superfície de célula não-nativo, ao qual liga-se um adenovírus tendo um ligante para o receptor, e um método de propagar um adenovírus utilizando a linhagem de célula. A presente invenção também provê um método de purificar um adenovírus tendo um ligante para um substrato de uma composição compreendendo o adenovírus. O método envolve a exposição da composição ao substrato, sob condições que promovem o ligante a ligar-se, seletivamente, ao substrato. A presente invenção provê, ainda, um método de inativar um adenovírus tendo um ligante que reconhece um substrato carregado por linfa ou sangue, expondo o vírus ao substrato. No sangue ou linfa, o ligante liga seu substrato, adsorvendo, deste modo, o vírus livre do sangue ou linfa. Adicionalmente, a presente invenção provê uma proteína de bloqueio quimérica, compreendendo um substrato para uma fibra de adenovírus, e um método para interferir com a ligação de receptor adenoviral, incubando um adenovírus com tal proteína de bloqueio quimérica, em uma solução tal que a proteína de bloqueio quimérica liga a fibra.
BR9809173-5A 1997-05-28 1998-05-28 Adenovìrus alternativamente direcionados BR9809173A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4784997P 1997-05-28 1997-05-28
US7166898P 1998-01-16 1998-01-16
PCT/US1998/011024 WO1998054346A1 (en) 1997-05-28 1998-05-28 Alternatively targeted adenovirus

Publications (1)

Publication Number Publication Date
BR9809173A true BR9809173A (pt) 2000-08-01

Family

ID=26725500

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809173-5A BR9809173A (pt) 1997-05-28 1998-05-28 Adenovìrus alternativamente direcionados

Country Status (10)

Country Link
EP (1) EP0988390A1 (pt)
JP (1) JP2001518806A (pt)
BR (1) BR9809173A (pt)
CA (1) CA2291323A1 (pt)
HU (1) HUP0002070A2 (pt)
IL (1) IL133010A0 (pt)
NZ (1) NZ501140A (pt)
PL (1) PL337130A1 (pt)
SK (1) SK159999A3 (pt)
WO (1) WO1998054346A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525065A (ja) * 1998-09-11 2002-08-13 ジェンベク、インコーポレイティッド 選択的にターゲッティングされるアデノウイルス
AU2869300A (en) * 1999-02-05 2000-08-25 Uab Research Foundation, The Fiber receptor-independent system for the propagation of adenoviral vectors
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
EP1593742A3 (en) * 1999-06-01 2006-02-01 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
EP1181382B1 (en) * 1999-06-01 2005-03-23 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
DK1272507T3 (da) 2000-04-12 2005-10-03 Amersham Health As Integrinbindende peptidderivater
AU2001252766A1 (en) * 2000-04-26 2001-11-07 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
EP1167533A1 (en) * 2000-06-23 2002-01-02 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Methods and means for the complementation of viral protein expression in stable cell lines
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
MXPA04000173A (es) 2001-07-10 2004-03-18 Amersham Health As Compuestos basados en peptidos.
FR2842823A1 (fr) * 2002-07-25 2004-01-30 Inst Nat Sante Rech Med Adenovirus modifies pour le ciblage des lymphocytes b
US20080124360A1 (en) 2003-01-24 2008-05-29 Seggern Daniel J Von Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
ES2340038T3 (es) 2003-11-14 2010-05-28 Genvec, Inc. Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
CA2563396A1 (en) 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP1951297A2 (en) 2005-11-10 2008-08-06 GenVec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
WO2010075058A1 (en) 2008-12-23 2010-07-01 Ge Healthcare Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
CA2779632C (en) 2009-11-09 2019-08-20 Jason Gall Simian adenovirus and methods of use
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
US9790519B2 (en) 2012-05-29 2017-10-17 Genvec, Inc. Modified serotype 28 adenoviral vectors
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
EP3072900A1 (en) * 2015-03-27 2016-09-28 Medizinische Hochschule Hannover Anti-tumour medicament based on adenovirus
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same

Also Published As

Publication number Publication date
SK159999A3 (en) 2000-06-12
WO1998054346A1 (en) 1998-12-03
EP0988390A1 (en) 2000-03-29
JP2001518806A (ja) 2001-10-16
PL337130A1 (en) 2000-07-31
HUP0002070A2 (hu) 2000-10-28
CA2291323A1 (en) 1998-12-03
NZ501140A (en) 2001-07-27
IL133010A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
BR9809173A (pt) Adenovìrus alternativamente direcionados
Tarsio et al. Decreased interaction of fibronectin, type iv collagen, and heparin due to nonenzymic glycation. Implications for diabetes mellitus
Arnon et al. Recognition of viral hemagglutinins by NKp44 but not by NKp30
Ohta et al. The mechanism of carbohydrate-mediated complement activation by the serum mannan-binding protein.
Jenke et al. An episomally replicating vector binds to the nuclear matrix protein SAF‐A in vivo
PT1140175E (pt) Anticorpos para o vegf-d truncado e suas utilizacoes
DE69232309T4 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
DK0930366T3 (da) Bindingsdomæner i Delta-proteiner
BR9815289A (pt) Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
BRPI0507019A (pt) composição, uso de anticorpo, anticorpo, uso de msrv/herv-w env-su
Rexin et al. Structure of the glucocorticoid receptor in intact cells in the absence of hormone.
CA2296737A1 (en) Ligand for herpes simplex virus entry mediator and methods of use
DE68922491D1 (de) Monoklonale antikörper gegen protein c.
IL134011A0 (en) Adipocyte-specific protein homologs
WO1994021800A3 (en) Protein tyrosine phosphatase ptp-s31
GB2368641A (en) Methods and compositions fo assaying analytes
DK0937153T3 (da) Humane monoklonale antistoffer, der er specifikke for hepatitis C-virus (HCV) E2 antigen
ATE542138T1 (de) Her-2-bindungsantagonisten
CA2524002A1 (en) Sars-related proteins
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
Sangeetha et al. IgA1 is the premier serum glycoprotein recognized by human galectin-1 since T antigen (Galβ1→ 3GalNAc-) is far superior to non-repeating N-acetyl lactosamine as ligand

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.